The pH-sensitive QD-MUC1-DOX conjugate released DOX from the payload only after the QD-MUC1-DOX had been internalized into MUC1-overexpressing ovarian cancer cells to avoid any MDR, which ultimately improved the efficacy of the therapeutics (Savla et al., 2011). The gene discussed is MUC1; the disease is ovarian cancer.